Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Drops By 80.8%

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 174,100 shares, a decline of 80.8% from the January 15th total of 909,000 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average daily volume of 4,260,000 shares, the short-interest ratio is presently 0.0 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “neutral” rating and issued a $7.00 price target on shares of Windtree Therapeutics in a report on Wednesday, December 4th.

Windtree Therapeutics Stock Up 15.0 %

WINT traded up $0.02 during trading on Wednesday, reaching $0.18. The company had a trading volume of 110,170,237 shares, compared to its average volume of 12,938,791. The stock has a market cap of $2.03 million, a P/E ratio of -0.01 and a beta of 0.53. The business has a 50 day simple moving average of $0.26 and a 200-day simple moving average of $2.61. Windtree Therapeutics has a 52 week low of $0.10 and a 52 week high of $14.75.

Windtree Therapeutics (NASDAQ:WINT) last released its earnings results on Tuesday, November 26th. The company reported ($4.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.27) by ($1.96). As a group, equities research analysts expect that Windtree Therapeutics will post -5.66 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.